NCT05650242View on ClinicalTrials.gov

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1106 in Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

177

Participants

Timeline

Start Date

January 31, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Solid Tumors

Interventions

DRUG

BA1106

"In part A, after the observation period of DLT (28 days), intravenous (IV) once every 3 weeks (Q3W).~In Part B, intravenous (IV) once every 3 weeks (Q3W) or once every 2 weeks (Q2W)."

Trial Locations (1)

10036

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors

lead

Shandong Boan Biotechnology Co., Ltd

INDUSTRY